ArticlePharmacogenomics2014
Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics.
Article in Pharmacogenomics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 42 citations in OpenAlex.
- Search for Novel Biomarkers to Predict Cytochrome P450 2C19 Activity Using Untargeted Metabolomics of Human Plasma.Metabolites · 2026Article
- Rudolf Buchheim Award 2026: solanidine as a dietary derived CYP2D6 biomarker.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Liquid Chromatography-Tandem Mass Spectrometry Quantification of Diet-Derived CYP2D6 Biomarkers for Clinical Phenotyping in Japanese Subjects.Clinical and translational science · 2026Article
- Solanidine is a sensitive and specific dietary biomarker for CYP2D6 activity.Human genomics · 2024Article
- Prediction of CYP2D6 poor metabolizers by measurements of solanidine and metabolites-a study in 839 patients with known CYP2D6 genotype.European journal of clinical pharmacology · 2023Review
- Categorization of Cytochrome P4502D6 Activity Score by Urinary Amphetamine/Methamphetamine Ratios.Metabolites · 2022Article
- Recent advances in the ontogeny of drug disposition.British journal of clinical pharmacology · 2022Review
- Innovative approaches and recent advances in the study of ontogeny of drug metabolism and transport.British journal of clinical pharmacology · 2022Review
- Isolation and Identification of 3,4-Seco-Solanidine-3,4-dioic acid (SSDA) as a Urinary Biomarker of Cytochrome P450 2D6 (CYP2D6) Activity.Drug metabolism and disposition: the biological fate of chemicals · 2022Article
- Metabolomics reveals biomarkers in human urine and plasma to predict cytochrome P450 2D6 (CYP2D6) activity.British journal of pharmacology · 2021Article
- Serum Predose Metabolic Profiling for Prediction of Rosuvastatin Pharmacokinetic Parameters in Healthy Volunteers.Frontiers in pharmacology · 2021Article
- A Review of the Important Role ofGenes · 2020Review
- Normalized Testosterone Glucuronide as a Potential Urinary Biomarker for Highly Variable UGT2B17 in Children 7-18 Years.Clinical pharmacology and therapeutics · 2020Article
- Toward precision medicine in pediatric population using cytochrome P450 phenotyping approaches and physiologically based pharmacokinetic modeling.Pediatric research · 2020Review
- Long-Distance Phasing of a Tentative "Enhancer" Single-Nucleotide Polymorphism WithFrontiers in pharmacology · 2020Article
- Phenotyping of Human CYP450 Enzymes by Endobiotics: Current Knowledge and Methodological Approaches.Clinical pharmacokinetics · 2019Review
- Biomarker Discovery for Cytochrome P450 1A2 Activity Assessment in Rats, Based on Metabolomics.Metabolites · 2019Article
- The reproducibility of urinary ions in manganese exposed workers.Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) · 2019Article
- The Use of Metabolomics to Identify Biological Signatures of Manganese Exposure.Annals of work exposures and health · 2017Article
- Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy.Metabolomics : Official journal of the Metabolomic Society · 2017Article
Corrections and comments
- Erratum issuedCorrigendum.2015
- Erratum issuedCorrigendum.2015
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
Abstract
aimWe sought to discover endogenous urinary biomarkers of human CYP2D6 activity. PATIENTS &
methodsHealthy pediatric subjects (n = 189) were phenotyped using dextromethorphan and randomized for candidate biomarker selection and validation. Global urinary metabolomics was performed using liquid chromatography quadrupole time-of-flight mass spectrometry. Candidate biomarkers were tested in adults receiving fluoxetine, a CYP2D6 inhibitor.
resultsA biomarker, M1 (m/z 444.3102) was correlated with CYP2D6 activity in both the pediatric training and validation sets. Poor metabolizers had undetectable levels of M1, whereas it was present in subjects with other phenotypes. In adult subjects, a 9.56-fold decrease in M1 abundance was observed during CYP2D6 inhibition.
conclusionIdentification and validation of M1 may provide a noninvasive means of CYP2D6 phenotyping.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.